Clinical Trial: A multicenter, open-label Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BY101921 in combination with PD-1 monoclonal antibody in patients with advanced malignant solid tumours. (China)

China, Nov. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A multicenter, open-label Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BY101921 in combination with PD-1 monoclonal antibody in patients with advanced malignant solid tumours.'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136458

Registration Time: 2026/11/11

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=265819

Published by HT Di...